{
    "summary": "This bill, the \"Preserving Life-saving Access to Specialty Medicines in America Act\" (PLASMA Act), amends Title XVIII of the Social Security Act to provide a phased-in manufacturer discount for plasma-derived products under the Medicare Part D program. The discount percentage will vary based on the year (2026-2032+) and whether the beneficiary has met their out-of-pocket threshold. Certain drugs dispensed to low-income subsidy (LIS) beneficiaries and those from specified small manufacturers are excluded.",
    "tags": [
        "Healthcare",
        "Social security",
        "Healthcare access",
        "Elderly care"
    ],
    "category": "Healthcare & Public Health"
}